OS Therapies (OSTX)
NYSE: OSTX
· Real-Time Price · USD
1.67
0.04 (2.45%)
At close: Jun 06, 2025, 3:59 PM
1.64
-1.74%
After-hours: Jun 06, 2025, 05:49 PM EDT
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OS Therapies

Country | United States |
IPO Date | Aug 1, 2024 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Paul A. Romness M.P.H. |
Contact Details
Address: 15825 Shady Grove Road Suite 135 Rockville, Maryland United States | |
Website | https://ostherapies.com |
Stock Details
Ticker Symbol | OSTX |
Exchange | NYSE |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001795091 |
CUSIP Number | n/a |
ISIN Number | US68764Y2072 |
Employer ID | 82-5118368 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Paul A. Romness M.P.H. | Founder, Chairman, President & Chief Executive Officer |
Christopher P. Acevedo | Chief Financial Officer |
Dr. Robert G. Petit Ph.D. | Chief Medical Officer & Chief Scientific Officer |
Gerald E. Commissiong | Chief Business Officer |
Jack Doll | Chief of Staff |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 23, 2025 | S-1 | Filing |
May 16, 2025 | 8-K | Current Report |
May 15, 2025 | 10-Q | Quarterly Report |
May 09, 2025 | 4 | Filing |
May 09, 2025 | SCHEDULE 13D/A | [Amend] Filing |
May 09, 2025 | 4 | Filing |
Apr 21, 2025 | POS AM | Filing |
Apr 21, 2025 | POS AM | Filing |
Apr 16, 2025 | SCHEDULE 13G | Filing |
Apr 15, 2025 | 8-K | Current Report |